In a major move to expand patient access to blockbuster weight-loss and diabetes treatments, Novo Nordisk announced Tuesday that it will significantly reduce the U.S. list prices for Wegovy, Ozempic and Rybelsus starting next year.
Effective Jan. 1, 2027, the company will set a uniform list price of $675 per month across all doses of its semaglutide portfolio. This represents a roughly 50% reduction for the weight-loss drug Wegovy and a 35% cut for the diabetes treatment Ozempic.
The price cut is specifically aimed at patients who feel the “sticker shock” of pharmacy costs most acutely: those with high-deductible health plans or co-insurance, where out-of-pocket costs are often calculated as a percentage of the medicine’s list price.
“Private and public payers, as well as patients, want access and have been calling for lower list prices,” Jamey Millar, executive vice president of U.S. Operations at Novo Nordisk said. “Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients.”
The New Pricing Structure (Effective Jan. 1, 2027)
| Medication | Current Status | New Monthly List Price | Estimated Reduction |
| Wegovy® (Injection/Tablets) | Obesity & Cardiovascular Risk | $675 | ~50% |
| Ozempic® (Injection) | Type 2 Diabetes & Chronic Kidney Disease | $675 | ~35% |
| Rybelsus® (Tablets) | Type 2 Diabetes | $675 | Significant Reduction |
The timing of the announcement coincides with Novo Nordisk’s efforts to steer patients away from compounded or “copycat” versions of semaglutide. With supply levels now fully available nationwide in the U.S., the company emphasized that patients no longer need to rely on unapproved alternatives.
“There is no reason for patients to gamble with their health with knock-off products produced by compounders,” the company stated, pointing patients toward FDA-approved channels.
Unlike other medications in the GLP-1 class, semaglutide has secured a wide range of FDA-approved uses that go beyond weight loss and blood sugar management. These include:
- Chronic Kidney Disease: Reducing the risk of worsening disease in adults with type 2 diabetes.
- Cardiovascular Health: Reducing the risk of heart attack, stroke, or death in adults with known heart disease.
While the list price reduction doesn’t take effect until 2027, Novo Nordisk continues to offer intermediate relief through its NovoCare® savings offers and self-pay pharmacy options. The company noted that these new list price changes will not negatively impact existing direct-to-patient, self-pay pricing.
Headquartered in Plainsboro, Novo Nordisk has maintained a U.S. presence for over 40 years, employing roughly 10,000 people across the country.
